Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

71.01USD
20 Jan 2017
Change (% chg)

$-0.56 (-0.78%)
Prev Close
$71.57
Open
$71.97
Day's High
$72.00
Day's Low
$70.58
Volume
3,347,982
Avg. Vol
2,837,979
52-wk High
$103.09
52-wk Low
$70.58

GILD.OQ

Chart for GILD.OQ

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $93,552.55
Shares Outstanding(Mil.): 1,317.46
Dividend: 0.47
Yield (%): 2.65

Financials

  GILD.OQ Industry Sector
P/E (TTM): 6.59 44.85 30.38
EPS (TTM): 10.78 -- --
ROI: 35.14 -1.38 14.86
ROE: 87.95 -1.07 16.28

BRIEF-European Medicines Agency validates Gilead's marketing authorization application for investigational chronic hepatitis C therapy

* European Medicines Agency validates Gilead's marketing authorization application for investigational chronic hepatitis c therapy sofosbuvir/velpatasvir/voxilaprevir (sof/vel/vox)

Jan 20 2017

Investors in big pharma, biotech look to ride out Trump storm

NEW YORK, Jan 12 Investors in large U.S. pharmaceutical and biotech companies are counting on strong dividends, reasonable stock valuations and new products to help ride out a storm of political uncertainty as the incoming Trump administration dives into healthcare policy.

Jan 12 2017

BRIEF-European Commission grants marketing authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the treatment of chronic hepatitis B virus infection

* European Commission grants marketing authorization for Gilead's Vemlidy (Tenofovir Alafenamide, TAF) for the treatment of chronic hepatitis B virus infection Source text for Eikon: Further company coverage:

Jan 11 2017

BRIEF-Gilead COO says slowdown in patients starting hep C therapies to continue in 2017

* Gilead exec says slowdown in patients starting hepatitis c therapies to continue in 2017

Jan 09 2017

BRIEF-Gilead Sciences planning Phase III NASH trials

* CEO says planning Phase III trials of NASH drug in patients with advanced fibrosis Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)

Jan 09 2017

BRIEF-Immuron Ltd says Gilead pays $100M NASH related milestone to Phenex

* Gilead pays $100M NASH related milestone to Phenex Source text for Eikon: Further company coverage:

Jan 08 2017

Gilead poaches Novartis cancer specialist Riva

ZURICH Gilead Sciences has hired a top cancer specialist from Swiss drugmaker Novartis as the U.S. healthcare group sharpens its focus on oncology.

Jan 04 2017

Merck wins $2.54 billion in hepatitis C drug trial against Gilead

Merck & Co on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead Sciences Inc over Gilead's blockbuster hepatitis C drugs Sovaldi and Harvoni.

Dec 15 2016

Trump's corporate tax holiday could spur pharma M&A

U.S. President-elect Donald Trump's plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth.

Dec 06 2016

Switching course, Gilead markets HIV drug for prevention

NEW YORK Gilead Sciences Inc has begun marketing its HIV treatment Truvada in a way thousands of consumers already use it – to prevent infection with the virus that causes AIDS.

Nov 30 2016

Competitors

Earnings vs. Estimates